Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
about
Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221Microbubble-enhanced ultrasound exposure improves gene transfer in vascular endothelial cells.Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot studyENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs.Heparanase and hepatocellular carcinoma: promoter or inhibitor?A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor.Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines.A multidisciplinary approach to the management of hepatocellular carcinoma.Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies.Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients.Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinomaCharacterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities.Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinomaEndothelial cells do not arise from tumor-initiating cells in human hepatocellular carcinoma.Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Thalidomide and irradiation combination therapy increases substance P levels in vitroNeovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA.Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potentialHuman lung cancer-derived microparticles enhanced angiogenesis and growth of hepatoma cells in rodent lung parenchymaEffective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model.Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma.Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.Current concepts in pediatric liver tumors.Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea.Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine.Angiogenesis in liver regeneration and fibrosis: "a double-edged sword".PSG9 promotes angiogenesis by stimulating VEGFA production and is associated with poor prognosis in hepatocellular carcinoma.Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway.
P2860
Q24631381-94C6E68D-BF09-4E87-8FA9-36C7D9769FA5Q30433371-E7E1262B-FF71-49FA-AEA5-9B5A81CAC584Q30460933-63AEF5D1-B218-466F-AE72-C846BECECBDAQ33354649-B8B9A9A2-649E-45AD-B3D1-E7C63CCF55A8Q33523861-C92F1F91-6ED6-4B92-8080-B9CA3EC79168Q33596487-17141282-4ACD-440A-A740-BB6AA94D907CQ33606606-76AA6808-A85C-4908-A268-E6B89F654BA2Q33747394-FB3AC6C0-DC28-4D98-A94D-43384D2D4B41Q33898852-0A7D1D7A-8444-482D-8D2C-EE8B3E93F145Q33916361-05E487F3-2156-44A9-AA4F-B86BE46F08A0Q33920350-82010342-CD25-48FD-80D9-DE094495C0CCQ34017735-3FBA8D29-F430-4D10-8B98-6A0540BD740EQ34114265-58EB5CF2-094A-441F-958A-5A0BCFD796FCQ34139199-B1DE202A-CE85-4D96-8547-EA79FE0B0CAFQ34593345-158DE8AC-8127-47D8-BFFA-20BBD33D94E6Q34644926-ADD15639-5FF1-4692-BE57-239E9F37F4B5Q34900837-5B700FA6-CDAA-4D2B-90EC-14A055743F70Q35014219-B8483479-C032-4860-AE27-F9B8777EF544Q35020519-4CD0290B-6784-4A03-A954-888A72887098Q35856029-2A4A3E68-AB2B-42DB-A510-686A9343B128Q36182824-302916D2-34DA-47E5-BB97-1BB96D70AE5CQ36230673-F4FB1D84-95F5-42B6-8CF7-9BE205115DAEQ36285676-89162C78-5704-4A83-AEAB-13A95B48453BQ36464350-A4E073F8-88F0-449F-B88F-9AA8E3E95C4EQ36563082-B0C145EA-E7F2-4BBC-9512-486C5A774B80Q36623880-36B3DABA-54E0-4068-ADA5-F81A3B69050DQ36878519-EE6C74BA-D39C-450C-86E4-039C04244D98Q37286152-D13B42F7-7F59-4A02-9CC0-529ED51008CFQ37317180-F5124634-CEE9-41C2-B961-B0C7A5D39992Q37338042-3590601D-4A40-4C0A-95D4-BDACE9F2ADB5Q37461714-D3E8DC70-B08D-40E2-8E25-5B2C7BC743DAQ37463744-8542A407-47A2-4DAA-8225-207793408874Q37779804-760EEE48-85B0-4B2D-9887-92EED454F66EQ37989160-373A9835-9554-4305-B636-CF3B1ED7F225Q38007187-8F734C40-374F-464D-9620-B059F77D162FQ38158226-489D2A4F-726E-4E10-AE59-224DF7EE2F27Q38261140-F5A955CE-0E8B-458F-BC4A-DB7BF0D4B480Q38552296-6CC15E56-F6B5-40A4-ABC5-4AAB38812C35Q38721758-E4E0FF5A-03C1-4D32-9F28-2E409A6AC7F4Q38941385-8A684051-2141-4954-9975-E8AC49B7E6DC
P2860
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@ast
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@en
type
label
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@ast
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@en
prefLabel
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@ast
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@en
P1433
P1476
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
@en
P2093
Roberta Pang
Ronnie T P Poon
P304
P356
10.1016/J.CANLET.2006.01.008
P407
P577
2006-03-27T00:00:00Z